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Abstract
Background: Naproxen and naproxen sodium are non-steroidal anti-inflammatory drugs used in
a variety of painful conditions, including the treatment of postoperative pain. This review aims to
assess the efficacy, safety and duration of action of a single oral dose of naproxen/naproxen sodium
for moderate to severe acute postoperative pain in adults, compared with placebo.
Methods: The Cochrane Library (issue 4 2002), EMBASE, PubMed, MEDLINE and an in-house
database were searched for randomised, double blind, placebo controlled trials of a single dose of
orally administered naproxen or naproxen sodium in adults with acute postoperative pain. Pain
relief or pain intensity data were extracted and converted into dichotomous information to give
the number of patients with at least 50% pain relief over 4 to 6 hours. Relative benefit and number-
needed-to-treat were then calculated. The percentage of patients with any adverse event, number-
needed-to-harm, and time to remedication were also calculated.
Results: Ten trials with 996 patients in met the inclusion criteria. Six trials compared naproxen
sodium 550 mg (252 patients) with placebo (248 patients); the NNT for at least 50% pain relief over
six hours was 2.6 (95% confidence interval 2.2 to 3.2). There was no significant difference between
the number of patients experiencing any adverse event on treatment compared with placebo.
Weighted mean time to remedication was 7.6 hours for naproxen sodium 550 mg (206 patients)
and 2.6 hours for placebo (205 patients). Four other trials used lower doses.
Conclusion: A single oral dose of naproxen sodium 550 mg is an effective analgesic in the
treatment of acute postoperative pain. A low incidence of adverse events was found, although these
were not reported consistently.
Background
Naproxen and naproxen sodium are non-steroidal anti-
inflammatory drugs (NSAIDs) that inhibit prostaglandin
synthesis [1]. Naproxen is a derivative of propionic acid
and naproxen sodium is the sodium salt. Naproxen
sodium 550 mg is equivalent to 500 mg of naproxen [2].
Naproxen is clinically effective in patients with postoper-
ative pain [3]. The postoperative pain period is often
dominated by the need to find effective ways of blocking
the inflammatory reaction and relieving pain [4]. In one
US study, postsurgical pain was the leading cause of con-
cern in 57% of patients before surgery [5]. This concern is
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not misplaced. A survey of 3000 newly discharged
patients (surgical and medical) in UK hospitals showed
that 87% had moderate to severe pain in hospital, and
33% had pain that was present all or most of the time [6].
A recent, extensive review of postoperative pain manage-
ment found that severe pain, and poor or fair pain relief,
was experienced by almost one in five hospital patients
[7].
Specific data for the frequency of naproxen administra-
tion in postoperative pain are unavailable. However in
England in 2002 there were over 1.2 million prescriptions
for oral naproxen and naproxen sodium in primary care
[8]. The recommended daily dose of naproxen is 500 mg
or 1000 mg [9].
The use of conventional NSAIDs has been associated with
upper gastrointestinal bleeding and perforation, acute
liver injury, acute renal injury, and heart failure [10].
Complications are more likely to occur with chronic use
and NSAIDs generally present fewer risks if used short
term [11]. There is some evidence that naproxen may
reduce the risk of acute myocardial infarction [12–14].
Estimates of relative benefit and NNT (number-needed-
to-treat) can be derived from pain data [15]. The NNT is
the number of patients that need to be treated for one
patient to benefit from the active treatment who would
not have benefited from placebo. NNTs allows indirect
comparisons of different analgesics by looking at relative
efficacy, which are usually just as good as direct compari-
sons between different interventions [16].
Meta-analysis of individual trials is useful because it can
help to reduce the effect that chance plays on the final
result, giving a more precise estimate of drug efficacy than
looking at individual clinical trials alone [17,18]. It does
this by combining data from trials that are clinically
homogeneous, and reach a certain standard of trial
design; randomisation, blinding and placebo control are
important factors for reducing bias and chance effects
[19]. Inclusion of reports of low quality in meta-analysis
is likely to give misleading results [20], and therefore
assessments of report quality are important for determin-
ing whether trials should be included or excluded.
In acute pain trials the outcome most often reported is
total pain relief (TOTPAR) or summed pain intensity dif-
ference (SPID) over the four to six hours in which the
studies are usually conducted. These were therefore the
primary outcomes of interest, together with any informa-
tion on time to remedication and adverse events, of a sin-
gle dose of oral naproxen/naproxen sodium over 4 to 6
hours in the treatment of acute postoperative pain, from
meta-analysis of randomised, double blind, placebo con-
trolled clinical trials.
Methods
Relevant studies were sought regardless of language, pub-
lication type or publication status. The electronic data-
bases used were The Cochrane Library (Issue 4 2002), all
years and all databases; MEDLINE and PreMedline, all
years from 1966 to December 2002; EMBASE, all years
from 1980 to December 2002 and PubMed, all years from
1966 to December 2002. Since 1996 hand searching of
journals has been undertaken by part of the Cochrane
Collaboration. An in-house database containing hand
searched copies of randomised controlled trials in pain
for the years 1954 to 1995 [21], together with unpub-
lished trials held in-house containing individual patient
data, were also searched. Reference lists of retrieved arti-
cles were searched. Abstracts were not sought. Pharmaceu-
tical companies were not contacted.
The search strategy contained naproxen and "naproxen
sodium", together with registered brand names [2]. Full
details of the search strategy can be found in Additional
File 1. Potential trials were assessed by at least two review-
ers from abstracts retrieved in the search. If insufficient
information was given to determine if a trial should be
included, or if the abstract was not present, the complete
paper was located and assessed.
Studies were included if they were randomised, double
blind, placebo controlled clinical trials in which a single
oral dose of naproxen (or naproxen sodium) and a
matched placebo were administered to patients experienc-
ing moderate to severe baseline pain, following a surgical
procedure. Trials had to state patient reported pain relief
or pain intensity over 4 to 6 hours, measured using vali-
dated pain scales. These could be either, 1. a five-point cat-
egorical pain relief (PR) scale with standard or
comparable wording (none, slight, moderate, good, com-
plete), 2. a four-point categorical pain intensity (PI) scale
(none, mild, moderate, severe), 3. a 10 cm visual ana-
logue scale (VAS) for pain relief or pain intensity. Global
evaluations of patient reported pain relief over 4 to 6
hours were also considered acceptable, if measured on a
standard five-point scale.
For each potentially relevant trial, a quality assessment
scale was used to consider if it should be included in the
review. This employs a validated three item scale with a
maximum quality score of five [22]. A minimum of two
points (for randomisation and double blinding) were
required for a study to be included. Quality assessments
were made independently by at least two reviewers and
disputes settled by discussion between all reviewers.BMC Anesthesiology 2003, 3 http://www.biomedcentral.com/1471-2253/3/4
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The number of patients randomised into each treatment
group (intention to treat) was used in the efficacy analysis.
Mean TOTPAR (total pain relief) or mean SPID (summed
pain intensity difference) over 4 to 6 hours were either
extracted, or calculated from pain data within each trial.
These were converted into %maxTOTPAR or %maxSPID
(the percentage of the maximum possible total pain relief
or summed pain intensity), using verified equations [23–
26]. These data were used to calculate the number of
patients in each trial with at least 50% pain relief for both
active treatment and placebo. From this, NNTs were calcu-
lated with 95% confidence intervals [27]. Relative benefit
and relative risk estimates with 95% confidence intervals
were calculated using the fixed effects model [28]. A statis-
tically significant benefit of the active treatment over pla-
cebo was assumed when the lower limit of the 95%
confidence interval (CI) of the relative benefit was greater
than one. A statistically significant benefit of placebo over
active treatment was assumed when the upper limit of the
95% CI was less than one.
Homogeneity of trials was assessed visually [29] because
heterogeneity tests have been shown to be unhelpful
[30,31]. Funnel plots were not used to assess publication
bias as these have also been shown to be unhelpful
[32,33]. To determine if there was a significant difference
between NNTs for different doses of active treatment, or
between NNTs for equivalent doses of naproxen and
naproxen sodium, the z test [34] was used.
Secondary outcomes were extracted in those included
papers reporting them. These were (i) number of patients
remedicating following the initial dose, (ii) mean or
median time to remedication, (iii) reports of any adverse
event, (iv) reports of particular adverse events such as
headache or vomiting, and (v) reasons for patient discon-
tinuation or withdrawal. Weighted time to remedication
was calculated as follows. For each trial, the number of
patients taking active treatment was multiplied by the per-
centage remedicating by 12 hours. These values were
summed and divided by the total number of patients tak-
ing active treatment from all trials using remedication as
an outcome. Number-needed-to-harm (NNH) and rela-
tive risk were calculated for the number of patients in each
treatment group reporting any adverse event, and for spe-
cific events such as headache, dizziness, drowsiness etc, in
the same way as for NNTs. All calculations were per-
formed in Microsoft Excel X for the Macintosh. QUOROM
guidelines were followed.
Results
Fifty-nine potential papers were identified from the
search. One of these [35] could not be obtained from the
British Library. Forty-eight trials were excluded for at least
one of the following reasons. Thirty-one did not use pla-
cebo, seven had no 4 to 6 hour data, six did not measure
baseline pain or did not have moderate to severe baseline
pain, six had no extractable analgesic efficacy data, six
were not double blind, two used inappropriate pain scales
and one was not randomised. Full references and reasons
for exclusion can be seen in Additional File 2.
Ten studies [1,36–42] containing information from a
total of 996 patients met the selection criteria and were
included in the analysis. Two of the included studies were
currently unpublished, in which naproxen sodium 550
mg was used as an active comparator in acute dental pain
studies of rofecoxib [Merck Research Laboratories, unpub-
lished studies, 1997]. In the 10 trials 582 patients received
active treatment (505 naproxen sodium) and 414 received
placebo. One paper [41] reported on two trials conducted
at two separate hospitals, using two different doses of
active treatment, and was the only included study to use
naproxen rather than naproxen sodium. The results from
these two clinically homogeneous trials were combined to
give a weighted mean TOTPAR for naproxen 200 mg (40
patients), naproxen 400 mg (37 patients), and placebo
(40 patients), because the number of patients at hospital
two was very small.
All trials had a quality score of three or more, but only one
had a maximum score of five [37]. All included studies
were of six hours duration or longer. Five trials using
naproxen sodium 550 mg provided information on
remedication [37, 38, 42, unpublished studies]. These tri-
als were of 12 hours duration or longer.
The participants ranged in age from 14 to 72 years old. Six
hundred and eighty-two (68%) patients underwent dental
surgery, the rest either orthopaedic or general surgery. Full
details of the included studies can be found in Additional
File 3.
Efficiacy analysis
A summary of analgesic efficacy results for all doses can be
seen in Table 1. The z test showed no significant difference
between the NNTs for 550 mg, 400/440 mg and 200/220
mg doses of active treatment.
Naproxen sodium 550 mg v placebo
In six trials containing 500 patients, 252 received
naproxen sodium 550 mg and 248 received placebo.
The mean response rate (percentage of patients with at
least 50% pain relief) for naproxen sodium was 50% (127
patients out of 252), ranging from 30% to 72% in individ-
ual trials (Figure 1). The mean placebo response rate was
12% (30 patients out of 248), ranging from 6% to 19%.BMC Anesthesiology 2003, 3 http://www.biomedcentral.com/1471-2253/3/4
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Naproxen sodium 550 mg was significantly better than
placebo with relative benefit 4.2 (2.9 to 6.0). The NNT
was 2.6 (2.2 to 3.2) for at least 50% pain relief over six
hours in postoperative pain of moderate to severe
intensity.
Naproxen/naproxen sodium 400/440 mg v placebo
In three trials containing 334 patients, 210 received active
treatment and 124 received placebo. Thirty-seven of those
patients on active treatment were given naproxen 400 mg.
The mean active response rate was 49% (103 out of 210
patients), ranging from 46% to 53% in individual trials.
The mean placebo response rate was 11% (14 out of 124
patients), ranging from 5% to 23%.
Active treatment was significantly better than placebo
with relative benefit 4.8 (2.8 to 8.3). The NNT was 2.7
(2.2 to 3.5) for at least 50% pain relief over six hours in
postoperative pain of moderate to severe intensity.
Sensitivity analysis showed no significant difference
between NNTs for naproxen sodium 440 mg and
naproxen 400 mg.
Naproxen/naproxen sodium 200/220 mg v placebo
In two trials containing 202 patients, 120 received active
treatment and 82 received placebo. Forty of those patients
on active treatment were given naproxen 200 mg.
The mean active response rate was 45% (54 out of 120
patients), ranging from 30% to 53% in individual trials.
The mean placebo response rate was 16% (13 out of 82
patients), ranging from 10% to 23%.
Active treatment was significantly better than placebo
with relative benefit 2.9 (1.6 to 5.1). The NNT was 3.4
(2.4 to 5.8) for at least 50% pain relief over six hours in
postoperative pain of moderate to severe intensity.
The NNTs for naproxen 200 mg (2.3; 1.8 to 3.5) and
naproxen sodium 220 mg (13; 3.7 to no benefit) were dif-
ferent in two trials with 122 and 80 patients respectively.
Adverse events and withdrawals
Eight included studies reported adverse events for single
dose data [36–40, unpublished studies]. Only five trials
using naproxen sodium 550 mg contained sufficient eval-
uable data to pool results [36–38, unpublished studies
additional file 3]. Forty-seven out of 197 patients (24%)
given naproxen sodium 550 mg reported at least one
adverse event. Fifty-two out of 195 patients (27%) given
placebo reported at least one adverse event. There was no
significant difference between treatment and placebo, rel-
ative risk 0.89 (0.6 to 1.3). One patient given naproxen
sodium 440 mg had severe vomiting [1]. In another trial,
seven adverse events were "serious" in patients receiving
naproxen sodium 220 mg [39]. Investigators in both trials
did not regard these events as being related to the study
medication.
Patient withdrawals and exclusions were not reported
consistently. Trials often reported the total number of
exclusions or withdrawals without stating which treat-
ment groups these referred to. Neither was it clear exactly
when withdrawals occurred, ie, before assessment of anal-
gesia at 4–6 hours, of at some other point before the end
of the trial. Four trials did not give specific information for
the number of exclusions and patient withdrawals for a
single dose of naproxen/naproxen sodium [37, 41,
unpublished studies]. Of the remaining six trials, 45 out
of 354 patients assigned to treatment with naproxen
sodium were reported to have withdrawn or been
excluded. The majority of these (40/81) were in one trial
using naproxen sodium 220 mg [39] in which the reasons
for discontinuation were not stated. Adverse event related
withdrawals for naproxen/naproxen sodium were clearly
reported in three trials. These were one report of postop-
erative vomiting [1], one report of a headache (not
deemed due to study medication by the investigator) [40],
and Reicin et al. [42] reported that two patients out of 55
on naproxen sodium 550 mg and three patients out of 53
on placebo withdrew due to a clinically relevant adverse
event on day one of the study.
Table 1: Summary of analgesic efficacy results
Number of patients with at least 50% 
pain relief
Active treatment and dose (mg) Number of trials Naproxen Placebo Relative benefit (95% CI) NNT (95% CI)
Naproxen sodium 550 6 127/252 30/248 4.2 (2.9 to 6.0) 2.6 (2.2 to 3.2)
Naproxen sodium/naproxen 440/400 3 103/210 14/124 4.8 (2.8 to 8.3) 2.7 (2.2 to 3.5)
Naproxen sodium/naproxen 220/200 2 54/120 13/82 2.9 (1.6 to 5.1) 3.4 (2.4 to 5.8)BMC Anesthesiology 2003, 3 http://www.biomedcentral.com/1471-2253/3/4
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Remedication
Remedication data were pooled from four trials [37, 42,
unpublished studies] to give the percentage remedicating
by 12 hours, weighted by the number of patients. This was
63% (114 out of 181 patients) for naproxen sodium 550
mg and 78% (140 out of 180 patients) for placebo.
Results from five trials [37, 38, 42, unpublished studies]
were pooled to give the mean time to remedication,
weighted by the number of patients (Figure 2). For
naproxen sodium 550 mg this was 7.6 hrs (206 patients),
and for placebo it was 2.6 hours (205 patients).
Discussion
A single oral dose of 550 mg naproxen sodium has an
NNT of 2.6 (2.2 to 3.2) for at least 50% pain relief over six
hours in postoperative pain of moderate to severe inten-
sity, compared with placebo. This means that for approx-
imately every three patients given naproxen sodium 550
mg, one would achieve at least a 50% reduction in post-
operative pain of moderate to severe intensity who would
not have done so if given placebo. The most robust result
was for naproxen sodium 550 mg. This analysis contained
the most patients and is the most clinically relevant
because this is the dose commonly used.
For a single oral dose of naproxen/naproxen sodium 400/
440 mg the NNT was 2.7 (2.2 to 3.5). For 200/220 mg, the
NNT was 3.4 (2.4 to 5.8). Doses of less than 500 mg of
naproxen are not commonly used for acute postoperative
pain in clinical practice and are therefore of limited clini-
cal value. The results for naproxen/naproxen sodium 200/
220 mg and 400/440 mg are also less reliable than for
naproxen sodium 550 mg, because these analyses con-
tained fewer trials and fewer patients. Combining studies
into a meta-analysis may be better than relying on the
results from a single small trial, but meta-analysis based
on limited data may still not overcome chance effects
[17].
NNTs for 550 mg, 400/440 mg and 200/220 mg were sim-
ilar, but there was insufficient information from trials
using 440 mg doses or less to comment on dose response.
No increased effect with increased dose was found, but on
the limited information available it is not possible to
know whether there is no response or whether any
response is shallow or has been missed.
The relative efficacy of over 50 analgesics in acute postop-
erative pain has been compiled http://
www.jr2.ox.ac.ubandolier/booth/painpag/acutrev/anal-
gesics/leag tab.html Published versions can be found in
Edwards [43], Collins [44] and Moore [45]. The number
of patients in each meta-analysis from which NNTs have
been derived varies considerably, and should be taken
into account when comparing NNTs. A low NNT with a
narrow confidence interval suggests greater efficacy, and
the greater the number of patients in the meta-analysis the
more robust the NNT.
An NNT of 2.6 for naproxen sodium 550 mg is slightly
higher (worse) than ibuprofen 400 mg (2.4; 2.3 to 2.6),
but lower (better) than paracetamol 1000 mg (3.8; 3.4 to
4.4) and intramuscular morphine 10 mg (2.9; 2.6 to 3.6).
L'Abbé plot Figure 1
L'Abbé plot. Percentage of patients with at least 50% pain 
relief in placebo controlled clinical trials of naproxen sodium 
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Mean time to remedication Figure 2
Mean time to remedication. Mean time to remedication 
(hours) for naproxen sodium 550 mg and placebo in postop-
erative pain, compared with information on placebo, ibupro-
fen 400 mg and rofecoxib 50 mg [46].
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This meta-analysis did not compare naproxen/naproxen
sodium directly with other analgesics. However, indirect
comparisons such as these are still valid. A recent study of
44 meta-analyses has shown that in most cases, results of
adjusted indirect comparisons are not significantly differ-
ent from those of direct comparisons, with validity of
indirect comparisons depending on the internal validity
and similarity of the individual trials [16].
The mean time to remedication for naproxen sodium 550
mg was 7.6 hours (Figure 2). This is similar to that of ibu-
profen 400 mg at 7.4 hours, but shorter than for cox-2
selective inhibitors like rofecoxib 50 mg, at 13.6 hours, in
mainly dental pain trials [46]. Remedication in trials is a
useful marker for determining how long adequate analge-
sia lasts.
The major efficacy outcomes were total pain relief over 4–
6 hours (TOTPAR), and time to remedication in trials con-
ducted after third molar extraction and after other types of
surgery. Seven of 10 trials giving pain relief data, and three
of four giving time to remedication, were performed in
third molar extraction studies. Analysis has shown that
NNTs calculated for the outcome of half pain relief over
4–6 hours are the same in both these surgical categories,
in circumstances where oral analgesics were appropriate
[47]. Whether time to remedication is similar after dental
extraction and other postoperative circumstances is not
yet known.
There was no significant difference between the number
of patients reporting any adverse event for naproxen/
naproxen sodium compared with placebo. Trials report-
ing them did so less rigorously than for efficacy data and
the methodology for reporting adverse events varied
between studies. This is not unusual for adverse event
reporting in acute pain studies [48]. Withdrawals and
exclusions were reported even less well than adverse
events.
Conclusions
Naproxen sodium 550 mg is an effective analgesic in
adults with acute, moderate to severe postoperative pain.
Its NNT compares favourably with other analgesics. A low
incidence of adverse events was found but these were
poorly reported. Better reporting of information in trials,
particularly for adverse events, withdrawals and exclu-
sions, is required.
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